http://www.rxpgnews.com/ Medical News and Information Thu, 21 Aug 2008 02:00:28 PST en-us http://www.rxpgnews.com/cancer-vaccine/First_ever_shots_of_the_cervical_cancer_vaccine_ad_4900_4900.shtml Vaccination UQ Professor Ian Frazer administered the first shots of the cervical cancer vaccine Gardasil in Queensland this afternoon at the Princess Alexandra Hospital. Tue, 29 Aug 2006 03:41:00 PST http://www.rxpgnews.com/cancer-vaccine/First_ever_shots_of_the_cervical_cancer_vaccine_ad_4900_4900.shtml http://www.rxpgnews.com/cancer-vaccine/Scientists_one_step_closer_to_cancer_vaccine_3729_3729.shtml Vaccination Scientists at Karolinska Institutet in Sweden have helped to identify a molecule that can be used as a vaccination agent against growing cancer tumours. Although the results are so far based on animal experiments, they point to new methods of treating metastases. Wed, 22 Mar 2006 01:42:00 PST http://www.rxpgnews.com/cancer-vaccine/Scientists_one_step_closer_to_cancer_vaccine_3729_3729.shtml http://www.rxpgnews.com/cancer-vaccine/Response_to_Cancer_Vaccine_Enhanced_by_Chemotherap_2554_2554.shtml Vaccination A study of a cancer vaccine in mice has found that the vaccine induces a tumor-specific immune response that is enhanced when used with chemotherapy regimens that include 5-fluorouracil (5-FU). Wed, 05 Oct 2005 04:17:00 PST http://www.rxpgnews.com/cancer-vaccine/Response_to_Cancer_Vaccine_Enhanced_by_Chemotherap_2554_2554.shtml http://www.rxpgnews.com/cancer-vaccine/Ligand_Treatment_of_Treg_Cells_Enhanced_Anti-Tumor_2392_2392.shtml Vaccination A special stretch of genetic material may turn off the immune suppression that stymies attempts to fight cancer with a vaccine, said researchers at Baylor College of Medicine (BCM) at Houston. Wed, 14 Sep 2005 02:08:00 PST http://www.rxpgnews.com/cancer-vaccine/Ligand_Treatment_of_Treg_Cells_Enhanced_Anti-Tumor_2392_2392.shtml http://www.rxpgnews.com/cancer-vaccine/Prostate_Cancer_Vaccine_gets_Special_Protocol_Asse_1513_1513.shtml Vaccination Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for its second Phase 3 clinical trial of GVAX(R) vaccine for prostate cancer. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with binding written agreement that the design and analysis of the study are adequate to support a license application submission if the study is performed according to the SPA. Thu, 19 May 2005 09:35:00 PST http://www.rxpgnews.com/cancer-vaccine/Prostate_Cancer_Vaccine_gets_Special_Protocol_Asse_1513_1513.shtml http://www.rxpgnews.com/cancer-vaccine/A_Vaccine_For_Carcinoma_Cervix_538_538.shtml Vaccination Scientists have published results in the Lancet and New England Journal of Medicine that show that both vaccines protect against those two types of HPV, and now both vaccines are being studied in larger studies involving tens of thousands of women. The vaccines are given as a series of three shots given a few months apart. Fri, 04 Mar 2005 10:06:00 PST http://www.rxpgnews.com/cancer-vaccine/A_Vaccine_For_Carcinoma_Cervix_538_538.shtml http://www.rxpgnews.com/cancer-vaccine/Use_of_iNKT_cells_boosts_tumor_vaccination_strateg_145_145.shtml Vaccination T cell responses to natural infection are orders of magnitude greater than those observed in cancer patients in response to current vaccination protocols. Optimizing tumor vaccination protocols will require a deeper understanding of the signals that the immune system coordinates in order to respond to pathogenic infection. In the December 15 issue of the Journal of Clinical Investigation, Vincenzo Cerundolo and colleagues from the University of Oxford report a vaccination approach in mice in which intravenous delivery of a protein antigen plus a type of NK T cells, known as iNKT cells, enhanced the immune response and cleared an established tumor. Thu, 16 Dec 2004 17:51:00 PST http://www.rxpgnews.com/cancer-vaccine/Use_of_iNKT_cells_boosts_tumor_vaccination_strateg_145_145.shtml http://www.rxpgnews.com/cancer-vaccine/immune-cell-response_11.shtml Vaccination There are many therapeutic cancer vaccines designed to harness the immunological system to limit the growth or spread of cancer under investigation in early-phase clinical trials. However, the vast majority are being developed with little or no immunological monitoring to determine whether and how the human immune system is responding to the vaccine being studied. The Cancer Vaccine Collaborative (CVC), a partnership established by the Cancer Research Institute in New York and the international Ludwig Institute for Cancer Research (LICR), has announced that it is the first to demonstrate that vaccination with a cancer-specific recombinant protein antigen has successfully induced a fully integrated immunological response in humans. Thu, 04 Nov 2004 00:47:00 PST http://www.rxpgnews.com/cancer-vaccine/immune-cell-response_11.shtml